Lexeo Therapeutics, Inc. Common Stock
LXEO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $2 |
| % Growth | – | -100% | -60.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 | $2 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $74 | $53 | $49 | $45 |
| G&A Expenses | $32 | $15 | $12 | $7 |
| SG&A Expenses | $32 | $15 | $12 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $106 | $69 | $61 | $52 |
| Operating Income | -$106 | -$69 | -$61 | -$51 |
| % Margin | – | – | -9,252.1% | -3,055.9% |
| Other Income/Exp. Net | $7 | $2 | $1 | $0 |
| Pre-Tax Income | -$98 | -$66 | -$59 | -$51 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$98 | -$66 | -$59 | -$51 |
| % Margin | – | – | -9,063.8% | -3,055% |
| EPS | -3.09 | -2.49 | -2.36 | -2.01 |
| % Growth | -24.1% | -5.5% | -17.4% | – |
| EPS Diluted | -3.09 | -2.49 | -2.4 | -2.01 |
| Weighted Avg Shares Out | 32 | 27 | 25 | 25 |
| Weighted Avg Shares Out Dil | 32 | 27 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $0 |
| EBITDA | -$96 | -$64 | -$58 | -$51 |
| % Margin | – | – | -8,874.8% | -3,054.3% |